Niki BioSolutions is what remains of Aptorum Group after an all-stock combination with DiamiR Biosciences recast a cash-starved Cayman therapeutics vehicle as a Delaware diagnostics company. Control flipped to the diagnostics holders, the listing symbol changed, and the legal home moved to Princeton. What did not arrive with the close was a recapitalization. The combined laboratory and leftover pipeline still sit on a cash pile that covers roughly one more reporting period at the recent burn. Cash at the parent sat near $2 million at mid-year.
The strategic tension is that the public story is now a New Haven blood-test platform for Alzheimer disease, while the balance sheet is still a going-concern residual claim. The only large asset is an illiquid preferred stake in private Alzheon, carried near $15 million, pledged against a related-party note and encumbered by a special preferred claim on any exit. CogniMIR, the marketed risk assay, has published analytical validation and a planned clinical-validation window, but it has no Food and Drug Administration clearance in a market where C2N Diagnostics and Roche already sell cleared plasma tests. A first apolipoprotein E genotyping contract is the only named near-term cash engine, and the commercial terms were not disclosed.
Interim results through mid-year show no product revenue at the parent, a widened operating loss, and an explicit substantial-doubt paragraph. The half-year cash drain already consumed most of the starting cash. The question the next two prints resolve is whether pharma-services cash arrives before the next equity raise, or whether the mixed-securities shelf and the new incentive-plan reserve become the entire equity story.